Back to today’s briefing

Story perspectives

Amivantamab Shrinks Tumors in 42% of Refractory Head-Neck Cancer

5/31/2026

43 3 Full Breakdown

Summary

Story summary

Amivantamab shrank tumors in 42% of refractory head and neck cancer patients.
The trial enrolled 102 patients with metastatic head and neck cancer at 55 hospitals in 11 countries.
Patients received subcutaneous injections every three weeks, with median overall survival of 12.5 months and progression-free survival of 6.5 months.
The treatment caused moderate side effects, led fewer than ten patients to stop therapy, and blocked EGFR and MET.

1 of 1

Story summary

Amivantamab shrank tumors in 42% of refractory head and neck cancer patients.
The trial enrolled 102 patients with metastatic head and neck cancer at 55 hospitals in 11 countries.
Patients received subcutaneous injections every three weeks, with median overall survival of 12.5 months and progression-free survival of 6.5 months.
The treatment caused moderate side effects, led fewer than ten patients to stop therapy, and blocked EGFR and MET.